Roche Gets Atezolizumab Applications Rolling
This article was originally published in Scrip
Roche Holding AG is behind Merck & Co. Inc. and Bristol-Myers Squibb Co. in the commercial PD-1/PD-L1 immunotherapy race, but the Swiss company says its answer in the drug class, atezolizumab, has now started out on the regulatory road to approval amid high hopes for its therapeutic potential.
You may also be interested in...
Gesynta’s SEK190m ($20m) private placement allows its lead asset to enter Phase IIa studies for treating chronic inflammatory conditions in certain systemic sclerosis patients.
An expanded $120m series C financing will help Freeline advance its lead program in hemophilia B into a pivotal trial next year, CEO Theresa Heggie tells Scrip.
Novo Holdings’ REPAIR Impact Fund has opened a global ‘AMR talent contest’ to groups developing new antimicrobial treatments, offering direct investment as the prize.